182 related articles for article (PubMed ID: 8341645)
41. Chronic-relapsing experimental autoimmune encephalomyelitis (CR-EAE): treatment and induction of tolerance, with high dose cyclophosphamide followed by syngeneic bone marrow transplantation.
Karussis DM; Slavin S; Ben-Nun A; Ovadia H; Vourka-Karussis U; Lehmann D; Mizrachi-Kol R; Abramsky O
J Neuroimmunol; 1992 Aug; 39(3):201-10. PubMed ID: 1644896
[TBL] [Abstract][Full Text] [Related]
42. Treatment of minimal residual disease in myeloid leukemia--the immunotherapeutic options with emphasis on Linomide.
Rowe JM; Nilsson BI; Simonsson B
Leuk Lymphoma; 1993 Nov; 11(5-6):321-9. PubMed ID: 7510190
[TBL] [Abstract][Full Text] [Related]
43. Successful treatment of diabetes in NOD mice with advanced disease by islet isografts following immunoregulation with Linomide (quinoline-3-carboxamide).
Slavin S; Weiss L; Xia W; Gross DJ
Cell Transplant; 1996; 5(6):627-30. PubMed ID: 8951220
[TBL] [Abstract][Full Text] [Related]
44. The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis.
Brunmark C; Runström A; Ohlsson L; Sparre B; Brodin T; Aström M; Hedlund G
J Neuroimmunol; 2002 Sep; 130(1-2):163-72. PubMed ID: 12225898
[TBL] [Abstract][Full Text] [Related]
45. Acute/relapsing experimental autoimmune encephalomyelitis: induction of long lasting, antigen-specific tolerance by syngeneic bone marrow transplantation.
Karussis D; Vourka-Karussis U; Mizrachi-Koll R; Abramsky O
Mult Scler; 1999 Feb; 5(1):17-21. PubMed ID: 10096098
[TBL] [Abstract][Full Text] [Related]
46. Autoantigen-specific immunosuppression with tolerogenic peripheral blood cells prevents relapses in a mouse model of relapsing-remitting multiple sclerosis.
Kleist C; Mohr E; Gaikwad S; Dittmar L; Kuerten S; Platten M; Mier W; Schmitt M; Opelz G; Terness P
J Transl Med; 2016 May; 14(1):99. PubMed ID: 27131971
[TBL] [Abstract][Full Text] [Related]
47. Prevention of autoimmune diabetes by linomide in nonobese diabetic (NOD) mice is associated with up-regulation of the TCR-mediated activation of p21(ras).
Rapoport MJ; Weiss L; Mor A; Bistritzer T; Ramot Y; Slavin S
J Immunol; 1996 Nov; 157(10):4721-5. PubMed ID: 8906854
[TBL] [Abstract][Full Text] [Related]
48. Oral glatiramer acetate in experimental autoimmune encephalomyelitis: clinical and immunological studies.
Teitelbaum D; Aharoni R; Klinger E; Kreitman R; Raymond E; Malley A; Shofti R; Sela M; Arnon R
Ann N Y Acad Sci; 2004 Dec; 1029():239-49. PubMed ID: 15681762
[TBL] [Abstract][Full Text] [Related]
49. Experimental allergic encephalomyelitis. T cell trafficking to the central nervous system in a resistant Thy-1 congenic mouse strain.
Skundric DS; Huston K; Shaw M; Tse HY; Raine CS
Lab Invest; 1994 Nov; 71(5):671-9. PubMed ID: 7526038
[TBL] [Abstract][Full Text] [Related]
50. Treatment of relapsing autoimmune encephalomyelitis with T cell receptor V beta-specific antibodies when proteolipid protein is the autoantigen.
Whitham RH; Wingett D; Wineman J; Mass M; Wegmann K; Vandenbark A; Offner H
J Neurosci Res; 1996 Jul; 45(2):104-16. PubMed ID: 8843028
[TBL] [Abstract][Full Text] [Related]
51. Decreased CNS inflammation and absence of clinical exacerbation of disease after six months oral administration of bovine myelin in diseased SJL/J mice with chronic relapsing experimental autoimmune encephalomyelitis.
al-Sabbagh AM; Goad EP; Weiner HL; Nelson PA
J Neurosci Res; 1996 Aug; 45(4):424-9. PubMed ID: 8872902
[TBL] [Abstract][Full Text] [Related]
52. Decreased levels of pathogenic IgG anti-DNA antibodies in autoimmune mice after linomide treatment.
Spetz-Hagberg AL; Larsson-Sciard EL
Res Immunol; 1989; 140(5-6):517-25. PubMed ID: 2789418
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of experimental autoimmune neuritis by the immunomodulator linomide.
Karpati T; Karussis D; Abramsky O; Mizrahi-Koll R; Arbell I; Ovadia H
Immunol Lett; 1998 Oct; 63(3):141-5. PubMed ID: 9840682
[TBL] [Abstract][Full Text] [Related]
54. Linomide administration following bone marrow transplantation in mice.
Weiss L; Abdul-Hai A; Shufaro Y; Reich S; Slavin S
Cancer Immunol Immunother; 2002 Dec; 51(11-12):596-602. PubMed ID: 12439604
[TBL] [Abstract][Full Text] [Related]
55. Linomide-induced suppression of experimental autoimmune neuritis is associated with down-regulated macrophage functions.
Bai XF; Shi FD; Zhu J; Xiao BG; Hedlund G; Link H
J Neuroimmunol; 1997 Jun; 76(1-2):177-84. PubMed ID: 9184648
[TBL] [Abstract][Full Text] [Related]
56. Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-beta 1.
Racke MK; Dhib-Jalbut S; Cannella B; Albert PS; Raine CS; McFarlin DE
J Immunol; 1991 May; 146(9):3012-7. PubMed ID: 1707929
[TBL] [Abstract][Full Text] [Related]
57. Treatment of experimental encephalomyelitis with a novel chimeric fusion protein of myelin basic protein and proteolipid protein.
Elliott EA; McFarland HI; Nye SH; Cofiell R; Wilson TM; Wilkins JA; Squinto SP; Matis LA; Mueller JP
J Clin Invest; 1996 Oct; 98(7):1602-12. PubMed ID: 8833909
[TBL] [Abstract][Full Text] [Related]
58. The immune modulator Linomide prevents neuronal death in injured peripheral nerves of the mouse.
Ekström PA; Hedlund G; Karlsson J; Andersson G
Neuroreport; 1998 May; 9(7):1337-41. PubMed ID: 9631425
[TBL] [Abstract][Full Text] [Related]
59. Chronic experimental autoimmune encephalomyelitis induced by the 89-101 myelin basic protein peptide in B10RIII (H-2r) mice.
Jansson L; Olsson T; Höjeberg B; Holmdahl R
Eur J Immunol; 1991 Mar; 21(3):693-9. PubMed ID: 1707002
[TBL] [Abstract][Full Text] [Related]
60. Linomide, a novel immunomodulator that prevents death in four models of septic shock.
Gonzalo JA; González-García A; Kalland T; Hedlund G; Martínez C; Kroemer G
Eur J Immunol; 1993 Sep; 23(9):2372-4. PubMed ID: 8370414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
